Chemerin-9 (149-157)
- Product Name
- Chemerin-9 (149-157)
- CAS No.
- 676367-27-4
- Chemical Name
- Chemerin-9 (149-157)
- Synonyms
- Chemerin-9;Chemerin-9 (149-157);L-Serine, L-tyrosyl-L-phenylalanyl-L-prolylglycyl-L-glutaminyl-L-phenylalanyl-L-alanyl-L-phenylalanyl-
- CBNumber
- CB84713669
- Molecular Formula
- C54H66N10O13
- Formula Weight
- 1063.16
- MOL File
- 676367-27-4.mol
Chemerin-9 (149-157) Property
- storage temp.
- Store at -20°C
- solubility
- Soluble in DMSO
- Water Solubility
- Soluble to 1 mg/ml in water
Chemerin-9 (149-157) Chemical Properties,Usage,Production
Description
Chemerin-9 (149-157), the nonapeptide (149)YFPGQFAFS(157) (chemerin-9), corresponding to the C terminus of processed chemerin, retains most of the activity of the full-size protein, with regard to agonism toward the chemerinR[1].
Uses
Chemerin-9 (149-157) is a potent agonist of chemokine-like receptor 1 (CMKLR1) . Chemerin-9 (149-157) has anti-inflammatory activity. Chemerin-9 (149-157) stimulates phosphorylation of Akt and ERK as well as ROS production. Chemerin-9 (149-157) ameliorates Aβ1-42-induced memory impairmen. Chemerin-9 (149-157) regulates immune responses, adipocyte differentiation, and glucose metabolism[1][2][3][4].
in vivo
Chemerin-9 (149-157) (0.2 mg/kg; i.p.; daily, for 42 days) alleviates glucose intolerance and IR in PDM mice[1].
Chemerin-9 (149-157) (7.7? μg /kg; i.h.; daily, for 28 days) has anti-inflammatory and anti-angiogenic effects in ApoE-/- mice and protects the abdominal aorta from MMP damage[2].
Chemerin-9 (149-157) (8 μg/kg; ICV; daily; for 14 d; male Kunming mice) ameliorates Aβ1-42-induced memory impairment[3].
| Animal Model: | PDM mice[1] |
| Dosage: | 0.2 mg/kg |
| Administration: | Intraperitoneal injection; daily, for 42 days |
| Result: | Increased expression of chemerin, GLUT2, and PDX1, which led to the alleviation of glucose intolerance and IR in PDM model mice. |
| Animal Model: | ApoE-/- mice[2] |
| Dosage: | 7.7 μg /kg |
| Administration: | Subcutaneous injection; daily, for 28 days |
| Result: | Suppressed the enlargement of abdominal aorta and reversed the SMC loss. |
| Animal Model: | ApoE-/- mice[2] |
| Dosage: | 7.7 μg /kg |
| Administration: | Subcutaneous injection; daily, for 28 days |
| Result: | Down-regulated MMP2 and MMP-9 expression and decreased the levels of chemerin and CMKLR1. |
| Animal Model: | Male Kunming mice[3] |
| Dosage: | 8 μg/kg |
| Administration: | Intracerebroventrical injection; daily; for 14 days |
| Result: | Increased in the levels of pro-in?ammatory cytokines such as interleukin-1β (IL-1β), tumor necrosis factor (TNF-α) and interleukin-6 (IL-6) in the hippocampus. |
storage
Store at -20°C
References
[1]. Wittamer V, et al. The C-terminal nonapeptide of mature chemerin activates the chemerin receptor with low nanomolar potency. J Biol Chem. 2004 Mar 12;279(11):9956-62.
Chemerin-9 (149-157) Preparation Products And Raw materials
Raw materials
Preparation Products
Chemerin-9 (149-157) Suppliers
- Tel
- info@creative-peptides.com
- Country
- United States
- ProdList
- 6083
- Advantage
- 56
- Tel
- 16314854226; +16314854226
- inquiry@bocsci.com
- Country
- United States
- ProdList
- 19654
- Advantage
- 58
- Tel
- tp@aladdinsci.com
- Country
- United States
- ProdList
- 52923
- Advantage
- 58